The investigators retrospectively evaluated 126 consecutive treatment-naïve nAMD patients (126 eyes) who received a loading ...

The introduction of biosimilars in the treatment of age-related macular degeneration (AMD) is raising concerns among ...

aflibercept), a biosimilar to Eylea ® to treat multiple retinal disorders, including neovascular (wet) age-related macular degeneration (AMD), macular edema following retinal vein occlusion (RVO ...

Regeneron (REGN) faces a 3% stock drop after losing an appeals case over its Eylea drug patents against Amgen (AMGN).

Amgen’s biosimilar formulation is distinct from both the Regeneron patent covering Eylea and from the other biosimilars ... a way to prepare and formulate the active ingredient, aflibercept, in a ...

Regeneron Pharmaceuticals, Inc. faces Eylea revenue decline but shows growth potential with Dupixent & Libtayo. Click for ...

On March 5, 2025, the U.S. Court of Appeals for the Federal Circuit affirmed the District Court for the Northern District of West Virginia’s entry ...

28, 2012 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced that EYLEA ® (aflibercept) Injection has received approval for the treatment of patients with neovascular ...

Ixo-vec utilizes a proprietary vector capsid, AAV.7m8, carrying an aflibercept coding sequence under the control of a proprietary expression cassette and is designed to be administered as a one-time ...

In the randomized, sham-controlled ARTEMIS study, patients will receive either a dose of ixo-vec or a standard care regimen of anti-VEGF Eylea.

In addition to AVT06, which is a biosimilar candidate for Eylea ® (aflibercept) 2 mg, Alvotech is currently also developing AVT29, a biosimilar candidate for Eylea ® HD (aflibercept) 8 mg.

Earlier this month, the South Korean biosimilar maker secured approval for three other drugs from Europe: Eydenzelt, referencing blockbuster eye disease treatment Eylea; Stoboclo and Osenvelt.